AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32735426 — intervention group
Group type: COMPARATOR
Intervention: 1-minute rest interval (RI-1)
Number of subjects: 21
Study 32735426 — intervention group
Group type: COMPARATOR
Intervention: Control (15 minutes rest)
Number of subjects: 21
Study 34220712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ding-Kun Pill (DKP) 7g twice daily
Number of subjects: 462
Study 34220712 — intervention group
Group type: COMPARATOR
Intervention: Placebo 7g twice daily
Number of subjects: 462
Study 32331028 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (viewed a video of a scripted interview with a standardized patient actor depicting TD movements)
Number of subjects: 800
Study 32331028 — intervention group
Group type: COMPARATOR
Intervention: Control group (viewed the same actors but without TD movements)
Number of subjects: 800
Study 33449096 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided biopsy
Number of subjects: 20
Study 33449096 — intervention group
Group type: COMPARATOR
Intervention: Surgical pathology
Number of subjects: 20
Study 32216911 — intervention group
Group type: COMPARATOR
Intervention: Continuation of neurohumoral blocker therapy
Number of subjects: 80
Study 32216911 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of renin‐angiotensin‐aldosterone system inhibitors
Number of subjects: 80
Study 32216911 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of beta‐blockers
Number of subjects: 80
Study 32216911 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of renin‐angiotensin‐aldosterone system inhibitors and beta‐blockers
Number of subjects: 80
Study 32216911 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 80
Study 33402419 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 140 mg
Number of subjects: 246
Study 32197732 — intervention group
Group type: EXPERIMENTAL
Intervention: DIBSS-C abdominal score
Number of subjects: 0
Study 35751480 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection combined with finasteride and minoxidil
Number of subjects: 37
Study 35751480 — intervention group
Group type: COMPARATOR
Intervention: Control side (no botulinum toxin A injection)
Number of subjects: 37
Study 35751480 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A combined with finasteride and minoxidil
Number of subjects: 37
Study 32531982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic oligofructose-enriched inulin (10 g per day)
Number of subjects: 34
Study 32531982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 34
Study 35889769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination containing phytosterols, bergamot, olive fruits, and vitamin K2
Number of subjects: 118
Study 34034775 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) during CPR
Number of subjects: 588
Study 34034775 — intervention group
Group type: COMPARATOR
Intervention: Control group (flat position during CPR)
Number of subjects: 588
Study 33998356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastoscopic surgery
Number of subjects: 42
Study 33998356 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 42
Study 34081723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 61
Study 34081723 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women
Number of subjects: 61
Study 32877886 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES + PMT
Number of subjects: 60
Study 32877886 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT + PMT
Number of subjects: 60
Study 32877886 — intervention group
Group type: COMPARATOR
Intervention: PMT
Number of subjects: 60
Study 36240610 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low fixed dose of GH (0.1 mg/day)
Number of subjects: 18
Study 36240610 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of GH (initially 0.13 mg/day, increased to 0.31 mg/day)
Number of subjects: 18
Study 33377924 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized hemodynamic management using pleth variability index (PVI) aiming for PVI under 13%
Number of subjects: 438
Study 33377924 — intervention group
Group type: COMPARATOR
Intervention: Standard management strategy maintaining mean arterial pressure above 65 mmHg
Number of subjects: 438
Study 33377924 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized hemodynamic management using pleth variability index (PVI)
Number of subjects: 438
Study 36222197 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Number of subjects: 50
Study 36222197 — intervention group
Group type: COMPARATOR
Intervention: Cyclic rotary training
Number of subjects: 50
Study 32490551 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor 100 mg
Number of subjects: 100
Study 32490551 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor 30 mg
Number of subjects: 100
Study 32490551 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 35505681 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT, trunk-targeted PNF, and bihemispheric motor cortex stimulation with tDCS
Number of subjects: 54
Study 35505681 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT, trunk-targeted PNF, and sham tDCS
Number of subjects: 54
Study 35505681 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT) alone
Number of subjects: 54
Study 34275488 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of DMARDs
Number of subjects: 118
Study 34275488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided synovial biopsy
Number of subjects: 118
Study 34275488 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sampling and clinical evaluation
Number of subjects: 118
Study 34275488 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial biopsies
Number of subjects: 118
Study 34275488 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination of blood, urine, and synovium
Number of subjects: 118
Study 34275488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate statistical techniques
Number of subjects: 118
Study 34951717 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher oxygenation target (PaO2 of 12 kPa)
Number of subjects: 780
Study 34951717 — intervention group
Group type: COMPARATOR
Intervention: Lower oxygenation target (PaO2 of 8 kPa)
Number of subjects: 780
Study 33509921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial rtPA
Number of subjects: 984
Study 33509921 — intervention group
Group type: COMPARATOR
Intervention: No intra-arterial rtPA
Number of subjects: 984
Study 32007346 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT) for 40 hours
Number of subjects: 44
Study 32007346 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (CG)
Number of subjects: 44
Study 35162813 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic psychotherapy (STPP) with transference work
Number of subjects: 69
Study 35162813 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychoanalytic psychotherapy (STPP) without transference work
Number of subjects: 69
Study 35162813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both STPP groups (with and without transference work)
Number of subjects: 69
Study 32974999 — intervention group
Group type: EXPERIMENTAL
Intervention: Eriksson's theory of caritative caring
Number of subjects: 0
Study 32974999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercultural caring
Number of subjects: 0
Study 32974999 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring for patients suffering from addiction
Number of subjects: 0
Study 32974999 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic surroundings in nursing
Number of subjects: 0
Study 32974999 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership and education for nursing teachers
Number of subjects: 0
Study 36413383 — intervention group
Group type: EXPERIMENTAL
Intervention: bamlanivimab/etesevimab
Number of subjects: 319
Study 36413383 — intervention group
Group type: EXPERIMENTAL
Intervention: sotrovimab
Number of subjects: 319
Study 36413383 — intervention group
Group type: EXPERIMENTAL
Intervention: casirivimab/imdevimab
Number of subjects: 319
Study 32078058 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice rehabilitation (n=32)
Number of subjects: 66
Study 32078058 — intervention group
Group type: COMPARATOR
Intervention: No voice rehabilitation (n=34)
Number of subjects: 66
Study 33469728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GGS (freeze‐dried sulfonated human normal immunoglobulin)
Number of subjects: 32
Study 33469728 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (steroid pulse)
Number of subjects: 32
Study 32400000 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 28
Study 32400000 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole
Number of subjects: 28
Study 32400000 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + EDT (Leuprolide + Letrozole)
Number of subjects: 28
Study 616316807 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 405
Study 616316807 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 405
Study 35450742 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg once daily
Number of subjects: 102
Study 35450742 — intervention group
Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg per day
Number of subjects: 102
Study 35450742 — intervention group
Group type: EXPERIMENTAL
Intervention: combined solifenacin 5 mg and mirabegron 50 mg once daily
Number of subjects: 102
Study 35450742 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 102
Study 34919620 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthwash
Number of subjects: 30
Study 34919620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32872748 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout patients receiving anti-gout medication
Number of subjects: 179930
Study 32872748 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (no gout)
Number of subjects: 179930
Study 32571250 — intervention group
Group type: EXPERIMENTAL
Intervention: LCES (Lhasa Childhood Eye Study)
Number of subjects: 1856
Study 35050397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Training (CT)
Number of subjects: 53
Study 35050397 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 53
Study 35050397 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 53
Study 34080258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuts containing low-calorie diet (NELCD)
Number of subjects: 67
Study 34080258 — intervention group
Group type: COMPARATOR
Intervention: Nut-free energy-restricted diet (NFLCD)
Number of subjects: 67
Study 34080258 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NELCD and NFLCD)
Number of subjects: 67
Study 32267624 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrohysteropexy (LSH)
Number of subjects: 126
Study 32267624 — intervention group
Group type: COMPARATOR
Intervention: Sacrospinous hysteropexy (SSHP)
Number of subjects: 126
Study 33855908 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-guided IUD insertion
Number of subjects: 88
Study 33855908 — intervention group
Group type: EXPERIMENTAL
Intervention: USSA
Number of subjects: 88
Study 34354153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Arg:Lys ratio of 105% Arg relative to 10% higher Lys than NRC recommendations
Number of subjects: 576
Study 34354153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Arg:Lys ratio of 95% Arg relative to 10% higher Lys than NRC recommendations
Number of subjects: 576
Study 34354153 — intervention group
Group type: COMPARATOR
Intervention: Dietary Lys content at NRC recommendation
Number of subjects: 576
Study 34354153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Lys content at 10% higher than NRC recommendation
Number of subjects: 576
Study 33125399 — intervention group
Group type: EXPERIMENTAL
Intervention: Specifically composed music (Treated Group, TG)
Number of subjects: 0
Study 33125399 — intervention group
Group type: COMPARATOR
Intervention: Familiar music (Placebo Group, PG)
Number of subjects: 0
Study 33125399 — intervention group
Group type: COMPARATOR
Intervention: No music (Control Group, CG)
Number of subjects: 0
Study 34739002 — intervention group
Group type: EXPERIMENTAL
Intervention: Early metabolic support (EMS) with peripheral amino acid infusions
Number of subjects: 42
Study 34739002 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (enteral nutrition as soon as feasible)
Number of subjects: 42
Study 33822055 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine health information system
Number of subjects: 5795
Study 33822055 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assessment of health records
Number of subjects: 5795
Study 33822055 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing routine health information systems
Number of subjects: 5795
Study 35102518 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion-control plate with visual stimuli
Number of subjects: 76
Study 35102518 — intervention group
Group type: COMPARATOR
Intervention: Conventional plate
Number of subjects: 76
Study 34425228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota (specifically Methanobacteriaceae family, Desulfovibrionales order, Ruminiclostridium5 genus)
Number of subjects: 0
Study 34425228 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestive microbial taxa identified under nominal significance (P < 0.05)
Number of subjects: 0
Study 34059363 — intervention group
Group type: EXPERIMENTAL
Intervention: Original MethOd at pharmacy To ENhAnce Support for Health Improvement (OMOTENASHI)
Number of subjects: 71
Study 34059363 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication counselling method (CMC)
Number of subjects: 71
Study 34839248 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine‐Hydrochloride 0.5%
Number of subjects: 60
Study 34839248 — intervention group
Group type: COMPARATOR
Intervention: Sodium‐Chloride 0.9% (placebo)
Number of subjects: 60
Study 36385632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - trained crossing 50 suddenly-appearing virtual obstacles.
Number of subjects: 32
Study 36385632 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - merely walked on a treadmill.
Number of subjects: 32
Study 36385632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - trained with VR adaptation.
Number of subjects: 32
Study 36385632 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical obstacle avoidance at T1 and T2.
Number of subjects: 32
Study 32299097 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone mineral combined with enamel matrix derivative (test)
Number of subjects: 8
Study 32299097 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone mineral alone (control)
Number of subjects: 8
Study 33933825 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Training (BT)
Number of subjects: 96
Study 33933825 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 96
Study 33107439 — intervention group
Group type: EXPERIMENTAL
Intervention: Block and Replace (BR)
Number of subjects: 82
Study 33107439 — intervention group
Group type: COMPARATOR
Intervention: Dose Titration (DT)
Number of subjects: 82
Study 35793609 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2SeO3 (sodium selenite) continuous infusion at a pharmacological dose of 4 mg Se/day on day-1, followed by a high nutritional dose of 1 mg Se/day for 9 days
Number of subjects: 60
Study 35793609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33577767 — intervention group
Group type: EXPERIMENTAL
Intervention: aQIV
Number of subjects: 6761
Study 33577767 — intervention group
Group type: COMPARATOR
Intervention: Comparator vaccine
Number of subjects: 6761
Study 32103326 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontamination with polymyxin B, tobramycin, vancomycin, and amphotericin B, administered four times per day starting the day before surgery until postoperative day 7.
Number of subjects: 80
Study 32103326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (amphotericin B only), administered four times per day starting the day before surgery until postoperative day 7.
Number of subjects: 80
Study 32103326 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontamination with polymyxin B, tobramycin, vancomycin, and amphotericin B.
Number of subjects: 80
Study 32103326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (amphotericin B only).
Number of subjects: 80
Study 35776749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin intervention
Number of subjects: 0
Study 35776749 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendar-matched analysis
Number of subjects: 0
Study 35776749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-specified trial analysis
Number of subjects: 0
Study 35776749 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate adjustment methods
Number of subjects: 0
Study 35776749 — intervention group
Group type: EXPERIMENTAL
Intervention: Data augmentation approach
Number of subjects: 0
Study 32813949 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Number of subjects: 330
Study 32813949 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon
Number of subjects: 330
Study 33129455 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of toxic K. brevis (> 1 million cells L‐1) at normoxic levels (7.2 mg L‐1)
Number of subjects: 0
Study 33129455 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (1.5 mg L‐1) with high concentration of K. brevis
Number of subjects: 0
Study 33129455 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoxia (0.63 mg L‐1) with high concentration of K. brevis
Number of subjects: 0
Study 33129455 — intervention group
Group type: COMPARATOR
Intervention: Normoxic control (7.3 mg L‐1) with no K. brevis
Number of subjects: 0
Study 34641750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with asthma
Number of subjects: 236
Study 34641750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with asthma (asthma control levels)
Number of subjects: 236
Study 34641750 — intervention group
Group type: COMPARATOR
Intervention: Mothers without asthma
Number of subjects: 236
Study 33428652 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psychotic disorders
Number of subjects: 300
Study 33428652 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 300
Study 33428652 — intervention group
Group type: COMPARATOR
Intervention: Presence of a psychotic disorder
Number of subjects: 300
Study 33428652 — intervention group
Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 300
Study 33428652 — intervention group
Group type: COMPARATOR
Intervention: Never married status
Number of subjects: 300
Study 33428652 — intervention group
Group type: COMPARATOR
Intervention: Widowed/separated/divorced status
Number of subjects: 300
Study 33428652 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 300
Study 34130445 — intervention group
Group type: EXPERIMENTAL
Intervention: INSIGHT algorithm (adjusted by 1 unit/day)
Number of subjects: 129
Study 34130445 — intervention group
Group type: COMPARATOR
Intervention: EDITION algorithm (adjusted by 3 units/week)
Number of subjects: 129
Study 34130445 — intervention group
Group type: EXPERIMENTAL
Intervention: INSIGHT algorithm
Number of subjects: 129
Study 34130445 — intervention group
Group type: COMPARATOR
Intervention: EDITION algorithm
Number of subjects: 129
Study 33069888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 plus carboplatin (AUC 5 mg/mL/min) with pembrolizumab 200 mg (up to 2 years)
Number of subjects: 123
Study 33069888 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m2 plus carboplatin (AUC 5 mg/mL/min) without pembrolizumab (chemotherapy alone)
Number of subjects: 123
Study 32978116 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver + betahistine
Number of subjects: 100
Study 32978116 — intervention group
Group type: COMPARATOR
Intervention: Epley maneuver only
Number of subjects: 100
Study 34034784 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 specific monoclonal antibodies (mABs) authorized by the EUAs (bamlanivimab and etesevimab; casirivimab and imdevimab)
Number of subjects: 0
Study 32162808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential FOLFIRI followed by Cisplatin and Docetaxel
Number of subjects: 256
Study 32162808 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 256
Study 32162808 — intervention group
Group type: EXPERIMENTAL
Intervention: High inflammatory reaction
Number of subjects: 256
Study 32162808 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor PD-L1 ≥ 1% in sequential chemotherapy
Number of subjects: 256
Study 32162808 — intervention group
Group type: COMPARATOR
Intervention: Tumor PD-L1 <1%
Number of subjects: 256
Study 35627351 — intervention group
Group type: EXPERIMENTAL
Intervention: Core strength training (CST) programme (n = 16) performed thrice weekly
Number of subjects: 29
Study 35627351 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13) performing only sport-specific karate training
Number of subjects: 29
Study 33057670 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment as usual with adjunctive psycho-social intervention for medication adherence
Number of subjects: 167
Study 33057670 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual without adjunctive psycho-social intervention
Number of subjects: 167
Study 36167579 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus mindfulness meditation
Number of subjects: 165
Study 36167579 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture plus mindfulness meditation
Number of subjects: 165
Study 36167579 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture only
Number of subjects: 165
Study 36167579 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 165